Drug Trial Radar · NCT05620836
A Study to Evaluate the Efficacy and Safety of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa (HS)
Last checked: Nov 20, 2026Latest source record: Nov 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
619
Actual
Start
Feb 22, 2023
Primary completion
Jan 7, 2025
Study completion Nov 21, 2025
Sponsor
- Lead sponsor
- Incyte CorporationIncyte (INCY)
- Sponsor type
- Industry
- First posted
- Nov 17, 2022
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the efficacy and safety of Povorcitinib (INCB054707) in participants with moderate to severe Hidradenitis Suppurativa (HS) over a 12-week placebo-controlled period, followed by a 42-week extension period.
Conditions
- Hidradenitis Suppurativa (HS)
Interventions
PovorcitinibDrug
Oral, Tablet
PlaceboDrug
Oral, Tablet
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants Who Achieved Hidradenitis Suppurativa Clinical Response 50 (HiSCR50) at Week 12Time frame: Baseline; Week 12
Locations
101 sites in 11 countries. Site status is shown where the registry gives one.
Investigative Site US240
Scottsdale, Arizona
Investigative Site US237
Scottsdale, Arizona
Investigative Site US214
Arkansas City, Arkansas
Investigative Site US242
Fayetteville, Arkansas
Investigative Site US223
Los Angeles, California
Investigative Site US226
San Diego, California
Investigative Site US222
San Francisco, California
Investigative Site US233
Washington D.C., District of Columbia
Investigative Site US228
Brandon, Florida
Investigative Site US227
Margate, Florida
Investigative Site US204
Miami, Florida
Investigative Site US236
Miami, Florida
Investigative Site US200
Ocala, Florida
Investigative Site US201
Tampa, Florida
Investigative Site US220
West Dundee, Illinois
Investigative Site US206
Indianapolis, Indiana
Investigative Site US241
Iowa City, Iowa
Investigative Site US209
Louisville, Kentucky
Investigative Site US207
Metairie, Louisiana
Investigative Site US229
New Orleans, Louisiana
Investigative Site US224
Baltimore, Maryland
Investigative Site US208
Beverly, Massachusetts
Investigative Site US221
Quincy, Massachusetts
Investigative Site US213
Detroit, Michigan
Investigative Site US217
Waterford, Michigan
Investigative Site US212
Minneapolis, Minnesota
Investigative Site US239
Omaha, Nebraska
Investigative Site US230
Hightstown, New Jersey
Investigative Site US202
New York, New York
Investigative Site US210
Rochester, New York
Investigative Site US205
Chapel Hill, North Carolina
Investigative Site US215
Bexley, Ohio
Investigative Site US203
Columbus, Ohio
Investigative Site US232
Murfreesboro, Tennessee
Investigative Site US235
Arlington, Texas
Investigative Site US218
Bellaire, Texas
Investigative Site US238
Pflugerville, Texas
Investigative Site US234
San Antonio, Texas
Investigative Site AU205
Kogarah, New South Wales, Australia
Investigative Site AU203
Kotara, New South Wales, Australia
Showing 40 of 101 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.